Loading clinical trials...
Loading clinical trials...
An Open-label Extension Study of the Long-term Safety, Tolerability and Efficacy of Drisapersen in Subjects With Duchenne Muscular Dystrophy.
Conditions
Interventions
Drisapersen
Locations
39
United States
Kennedy Krieger Institute
Baltimore, Maryland, United States
IMAI Research
Buenos Aires, Argentina
Royal Children's Hosital, Children's Neuroscience Centre
Parkville, Victoria, Australia
Institute for Neuromuscular Research
Westmead, Australia
Queen Fabiola Children's University Hospital
Brussels, Belgium
Universitair Ziekenhuis Gent, Afdeling Neurologie
Ghent, Belgium
Last Updated
January 24, 2018
NCT06817382
NCT06839469
NCT07037862
NCT07160634
NCT06450639
NCT05016908
Lead Sponsor
BioMarin Pharmaceutical
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions